Xanomeline: A Potent and Selective M1 Muscarinic Agonist in Vitro

  • C. H. Mitch
  • F. P. Bymaster
  • D. O. Calligaro
  • S. J. Quimby
  • B. D. Sawyer
  • H. E. Shannon
  • J. S. Ward
  • P. H. Olesen
  • P. Sauerberg
  • M. J. Sheardown
  • P. D. Suzdak
  • Novo Nordisk
Part of the Advances in Behavioral Biology book series (ABBI, volume 44)

Abstract

Xanomeline (3-(4-Hexyloxy-1,2,5-thiadiazole-3-yl)-1,2,5,6-tetrahydro-1- methylpyridine), (hexyloxy-TZTP) was discovered in the course of investigations on the structure activity relationship of a series of thiadiazole based analogs of the muscarinic agonist arecoline. The compound demonstrated functional selectivity for M1 receptors when tested in isolated tissue preparations and in cloned cell lines expressing specific muscarinic receptor subtypes.

Keywords

Muscarinic Agonist Clone Cell Line Functional Selectivity Lilly Research Laboratory Muscarinic Receptor Type 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer Science+Business Media New York 1995

Authors and Affiliations

  • C. H. Mitch
    • 1
  • F. P. Bymaster
    • 1
  • D. O. Calligaro
    • 1
  • S. J. Quimby
    • 1
  • B. D. Sawyer
    • 1
  • H. E. Shannon
    • 1
  • J. S. Ward
    • 1
  • P. H. Olesen
    • 1
  • P. Sauerberg
    • 1
  • M. J. Sheardown
    • 1
  • P. D. Suzdak
    • 1
  • Novo Nordisk
    • 2
  1. 1.Lilly Research LaboratoriesEli Lilly and CompanyIndianapolisUSA
  2. 2.CNS DivisionMålØvDenmark

Personalised recommendations